|
 |
Pharmaceutical Manufacturing and Packing Sourcer
|
Taken from a marketing point of view, injectable therapeutics pose a challenge, for in these products there lies a conflict between two market influences: patients want to take the drug to get better, but they are frightened by the means of delivery. What makes marketing these technologies an even tougher business proposition for antibody therapeutics is that there is also a financial challenge: the difficulty of protecting a market for an antibody therapeutic using patents. Patents around a therapeutic target do not necessarily prevent a competitor developing a new antibody against it. Once a therapeutic target has been tested as clinically effective through the use of an antibody therapeutic, often competitor antibody developers can develop alternative therapeutics. This means that pharmaceutical companies need to look beyond the active therapeutic in order to make protein therapeutics commercially viable.
This proposition is tough, but it is also possible. There are, as I will demonstrate, success stories in injectable therapeutics - examples of how companies have managed their injectable product introductions and life cycle management. I will also examine in detail one specific route by which many pharmaceutical companies have sought to develop a competitive edge in this field. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Inaugural Conference on Pre-Filled Syringes
21-22 January 2009, Crowne Plaza Hotel - St James, London, UK
SMi present their Inaugural Conference on Pre-Filled Syringes 21st and 22nd January 2009 at the Crowne Plaza Hotel - St James, London, UK
More info >> |
|
 |
News and Press Releases |
 |
Ultra slim and ultra quick
More info >>
|
|
 |
